Prevalence of primary multidrug resistance to anti-tuberculosis drugs in Pakistan

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 3, 2008, Pages 326-331

  Javaid, Arshad ^a,p   Hasan, R ^b   Zafar, A ^b   Ghafoor, A ^c   Pathan, A J ^d   Rab, A ^e   Sadiq, A ^f   Akram, C M ^g   Burki, I ^h   Shah, K ⁱ   Ansari, M ^j   Rizvi, N ^k   Khan, S U ^l   Awan, S R ^l   Syed, Z A ^m   Iqbal, Z H ⁿ   Shaheen, Z ^m   Ur Rehman, N ^o  

^a LADY READING HOSPITAL   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c Provincial TB Control Program   (Pakistan)

^d Institute of Chest Diseases   (Pakistan)

^e AYUB TEACHING HOSPITAL   (Pakistan)

^f Ojha Institute of Chest Diseases   (Pakistan)

^g Gulab Devi Hospital   (Pakistan)

^h Lyari General Hospital   (Pakistan)

ⁱ National ARI Control Programme   (Pakistan)

^j Liaqat National Hospital   (Pakistan)

^k JINNAH POSTGRADUATE MEDICAL CENTRE   (Pakistan)

^l King Edwards Medical College   (Pakistan)

^m NISHTAR MEDICAL COLLEGE   (Pakistan)

ⁿ Allama Iqbal College of Physiotherapy   (Pakistan)

^o Wyeth (Pvt) Limited   (Pakistan)

^p NWFP ^*  (Pakistan)

more..

Author keywords

MDR TB; Pakistan; Primary drug resistance

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM ISOLATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PAKISTAN; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PAKISTAN; PREVALENCE; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 40549095298     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Dye C, Scheel S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance Monitoring Project. JAMA 1999; 282: 677-686.
2. World Health Organization, Communicable Diseases. Global tuberculosis control. WHO report 2001. WHO/CDS/TB/2001. 287. Geneva, Switzerland: WHO, 2001.
3. Pablos Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for anti-tuberculosis drug resistance 1994-1997. World Health Organization- International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338: 1641-1649.
4. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to anti-tuberculosis drugs. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
5. World Health Organization. Global tuberculosis control - surveillance, planning, financing. WHO report 2007. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
6. Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol 1993; 144: 104-110.
7. Kim S J, Hong Y F. Drug resistance of Mycobacterium tuberculosis in Korea. Tubercle Lung Dis 1992; 73: 219-224.
8. Chandrasekaran S, Jagota P, Chaudhury K, et al. Initial drug resistance to anti-tuberculosis drugs in urban and rural districts tuberculosis programme. Indian J Tuberc 1992; 39: 171-175.
9. Frieden T R, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
10. Van der Werf T S, Groothuis D G, van Klingeren B. High initial drug resistance in pulmonary tuberculosis in Ghana. Tubercle 1989; 70: 249-255.
11. Braun M M, Kilburn J O, Smithwick R W, et at. HIV infection and primary resistance to anti-tuberculosis drugs in Abidjan, Cote d'Ivoire. AIDS 1992; 6: 1327.
12. Paramasivan C N. An overview of drug resistant tuberculosis in India. Indian J Tuberc 1998; 45: 73.
13. World Health Organization. Surveillance of drug resistance in tuberculosis: a global random sample survey of initial and acquired resistance. WHO/TB. Geneva, Switzerland: WHO, 1984; 143: 1.
14. World Health Organization. Anti-tuberculosis drug resistance in the world (WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance - 1994-1997). WHO/TB/97-229. Geneva, Switzerland: WHO, 1997.
15. Chonde T M. The role of bacteriological surveys in the National Tuberculosis and Leprosy Programme in Tanzania. Bull Int Union Tuberc Lung Dis 1989; 64: 37-39.
16. Weyer K, Kleeberg H H. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of continuous drug resistance surveillance programme involvement. Tubercle Lung Dis 1992; 73: 106-112.
17. Paramasivan C N, Bhaskaraia K, Venkartaraman P, Chandrasekaran V, Narayanan P R. Surveillance of drug resistance in tuberculosis in the state of Tamil Nadu. Indian J Tuberc 2000; 47: 27-32.
18. Isenberg H D. Clinical microbiology procedure handbook. 2nd ed. Vol. 2. Washington, DC, USA: ASM Press, 2004: pp 7821-7823.
19. Wayne L G, Krasnow I. Preparation of tuberculosis susceptibility testing mediums by impregnated discs. Am J Public Health 1966; 45: 769-771.
20. Khan J. Drug resistance of Mycobacterium tuberculosis in Karachi. Trop Doct 1993; 23: 13-14.
21. Haq M, Awan S R. Sensitivity pattern of M. tuberculosis in Lahore, Pakistan. Annals King Edward Medical Coll 2002; 8: 190-193.